Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | VS-7375 |
| Synonyms | |
| Therapy Description |
VS-7375 (GFH375) selectively inhibits KRAS G12D, which potentially results in decreased cell proliferation and inhibition of tumor growth (Cancer Res (2024) 84 (6_Supplement): 3318). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| VS-7375 | VS 7375|VS7375|GFH 375|GFH-375|GFH375 | KRAS G12D Inhibitor 25 | VS-7375 (GFH375) selectively inhibits KRAS G12D, which potentially results in decreased cell proliferation and inhibition of tumor growth (Cancer Res (2024) 84 (6_Supplement): 3318). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT07020221 | Phase Ib/II | Carboplatin + Pembrolizumab + Pemetrexed Disodium + VS-7375 Gemcitabine + Nab-paclitaxel + VS-7375 Carboplatin + Pembrolizumab + Pemetrexed Disodium VS-7375 Gemcitabine + VS-7375 Cetuximab + VS-7375 | A Phase 1/2a Study of VS-7375 in Patients With KRAS G12D-Mutated Solid Tumors | Recruiting | USA | 0 |